The hematologic system as a marker of organ dysfunction in sepsis

Mayo Clinic Proceedings

Volumn 78, Issue 7, 2003, Pages 869-881

  Aird, William C ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANGIOTENSIN III; BLOOD SUBSTITUTE; ERYTHROPOIETIN; FLUOROCARBON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; LIVER ENZYME; TISSUE FACTOR PATHWAY INHIBITOR;

ANEMIA; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD DISEASE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CRITICAL ILLNESS; DISEASE MODEL; DISEASE SEVERITY; EARLY DIAGNOSIS; ERYTHROCYTE TRANSFUSION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; KIDNEY FUNCTION; LABORATORY TEST; LEUKOCYTOSIS; MYALGIA; NEUTROPENIA; NONHUMAN; REVIEW; SEPSIS; SURVIVAL; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

EID: 0038648796     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/78.7.869     Document Type: Review

References (138)

1. Marshall JC. SIRS and MODS: what is their relevance to the science and practice of intensive care? Shock. 2000;14:586-589.
2. Marshall JC. Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med. 2001;29(7, suppl):S99-S106.
3. Opal SM. Phylogenetic and functional relationships between coagulation and the innate immune response. Crit Care Med. 2000;28(9, suppl):S77-S80.
4. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation [published correction appears in N Engl J Med. 1999;340:1376]. N Engl J Med. 1999;340:448-454.
5. Tillema MS, Lorenz KL, Weiss MG, Dries DJ. Sublethal endotoxemia promotes pulmonary cytokine-induced neutrophil chemoattractant expression and neutrophil recruitment but not overt lung injury in neonatal rats. Biol Neonate. 2000;78:308-314.
6. Zahorec R. Ratio of neutrophil to lymphocyte counts - rapid and simple parameter of systemic inflammation and stress in critically ill [in English]. Bratisl Lek Listy. 2001;102:5-14.
7. Funke A, Berner R, Traichel B, Schmeisser D, Leititis JU, Niemeyer CM. Frequency, natural course, and outcome of neonatal neutropenia. Pediatrics. 2000;106(1, pt 1):45-51.
8. Shoup M, Weisenberger JM, Wang JL, Pyle JM, Gamelli RL, Shankar R. Mechanisms of neutropenia involving myeloid maturation arrest in burn sepsis. Ann Surg. 1998;228:112-122.
9. Quezado Z, Parent C, Karzai W, et al. Acute G-CSF therapy is not protective during lethal E. coli sepsis. Am J Physiol Regul Integr Comp Physiol. 2001;281:R1177-R1185.
10. Georges H, Leroy O, Vandenbussche C, et al. Epidemiological features and prognosis of severe community-acquired pneumococcal pneumonia. Intensive Care Med. 1999;25:198-206.
11. Kuhns DB, Alvord WG, Gallin JI. Increased circulating cytokines, cytokine antagonists, and E-selectin after intravenous administration of endotoxin in humans. J Infect Dis. 1995;171:145-152.
12. Michie HR, Manogue KR, Spriggs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med. 1988;318:1481-1486.
13. Adi S, Pollock AS, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C. Role for monokines in the metabolic effects of endotoxin: interferon-gamma restores responsiveness of C3H/HeJ mice in vivo. J Clin Invest. 1992;89:1603-1609.
14. Spittler A, Razenberger M, Kupper H, et al. Relationship between interleukin-6 plasma concentration in patients with sepsis, monocyte phenotype, monocyte phagocytic properties, and cytokine production. Clin Infect Dis. 2000;31:1338-1342.
15. Buttrum SM, Drost EM, MacNee W, et al. Rheological response of neutrophils to different types of stimulation. J Appl Physiol. 1994;77:1801-1810.
16. Huber-Lang MS, Younkin EM, Sarma JV, et al. Complement-induced impairment of innate immunity during sepsis. J Immunol. 2002;169:3223-3231.
17. Heller AR, Groth G, Heller SC, et al. N-acetylcysteine reduces respiratory burst but augments neutrophil phagocytosis in intensive care unit patients. Crit Care Med. 2001;29:272-276.
18. van der Poll T, van Deventer SJ. Cytokines and anticytokines in the pathogenesis of sepsis. Infect Dis Clin North Am. 1999;13:413-426.
19. Gao XP, Standiford TJ, Rahman A, et al. Role of NADPH oxidase in the mechanism of lung neutrophil sequestration and microvessel injury induced by Gram-negative sepsis: studies in p47phox-/- and gp91phox-/- mice. J Immunol. 2002;168:3974-3982.
20. Jaeschke H, Ho YS, Fisher MA, Lawson JA, Farhood A. Glutathione peroxidase-deficient mice are more susceptible to neutrophil-mediated hepatic parenchymal cell injury during endotoxemia: importance of an intracellular oxidant stress. Hepatology. 1999;29:443-450.
21. Root RK, Dale DC. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in nonneutropenic patients. J Infect Dis. 1999;179(suppl 2):S342-S352.
22. Ishikawa K, Tanaka H, Nakamori Y, et al. Difference in the responses after administration of granulocyte colony-stimulating factor in septic patients with relative neutropenia. J Trauma. 2000;48:814-824.
23. Ishikawa K, Tanaka H, Matsuoka T, Shimazu T, Yoshioka T, Sugimoto H. Recombinant human granulocyte colony-stimulating factor attenuates inflammatory responses in septic patients with neutropenia. J Trauma. 1998;44:1047-1054.
24. Heard SO, Fink MP, Gamelli RL, et al. Filgrastim Study Group. Effect of prophylactic administration of recombinant human granulocyte colony-stimulating factor (filgrastim) on the frequency of nosocomial infections in patients with acute traumatic brain injury or cerebral hemorrhage. Crit Care Med. 1998;26:748-754.
25. Gorgen I, Hartung T, Leist M, et al. Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor-alpha. J Immunol. 1992;149:918-924.
26. Hartung T, Docke WD, Gantner F, et al. Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood. 1995;85:2482-2489.
27. Bernstein HM, Pollock BH, Calhoun DA, Christensen RD. Administration of recombinant granulocyte colony-stimulating factor to neonates with septicemia: a meta-analysis. J Pediatr. 2001;138:917-920.
28. Held TK, Cross AS. Role of hematopoietic growth factors in non-neutropenic infections and sepsis. Curr Opin Hematol. 1999;6:176-183.
29. Baskurt OK, Gelmont D, Meiselman HJ. Red blood cell deformability in sepsis. Am J Respir Crit Care Med. 1998;157:421-427.
30. Langenfeld JE, Livingston DH, Machiedo GW. Red cell deformability is an early indicator of infection. Surgery. 1991;110:398-403.
31. Bateman RM, Jagger JE, Sharpe MD, Ellsworth ML, Mehta S, Ellis CG. Erythrocyte deformability is a nitric oxide-mediated factor in decreased capillary density during sepsis. Am J Physiol Heart Circ Physiol. 2001;280:H2848-H2856.
32. Powell RJ, Machiedo GW, Rush BF Jr, Dikdan G. Oxygen free radicals: effect on red cell deformability in sepsis. Crit Care Med. 1991;19:732-735.
33. Todd JC III, Poulos ND, Davidson LW, Mollitt DL. Role of the leukocyte in endotoxin-induced alterations of the red cell membrane: second place winner of the Conrad Jobst Award in the Gold Medal paper competition. Am Surg. 1993;59:9-12.
34. Lipowsky HH, Cram LE, Justice W, Eppihimer MJ. Effect of erythrocyte deformability on in vivo red cell transit time and hematocrit and their correlation with in vitro filterability. Microvasc Res. 1993;46:43-64.
35. Simchon S, Jan KM, Chien S. Influence of reduced red cell deformability on regional blood flow. Am J Physiol. 1987;253(4, pt 2):H898-H903.
36. Baskurt OK, Temiz A, Meiselman HJ. Red blood cell aggregation in experimental sepsis. J Lab Clin Med. 1997;130:183-190.
37. Su D, Roth RI, Levin J. Hemoglobin infusion augments the tumor necrosis factor response to bacterial endotoxin (lipopolysaccharide) in mice. Crit Care Med. 1999;27:771-778.
38. von Ahsen N, Muller C, Serke S, Frei U, Eckardt KU. Important role of nondiagnostic blood loss and blunted erythropoietic response in the anemia of medical intensive care patients. Crit Care Med. 1999;27:2630-2639.
39. Vincent JL, Baron JF, Reinhart K, et al. Anemia and Blood Transfusion in Critical Care Investigators. Anemia and blood transfusion in critically ill patients. JAMA. 2002;288:1499-1507.
40. Hebert PC, Wells G, Martin C, et al. Variation in red cell transfusion practice in the intensive care unit: a multicentre cohort study. Crit Care (Lond). 1999;3:57-63.
41. Groeger JS, Guntupalli KK, Strosberg M, et al. Descriptive analysis of critical care units in the United States: patient characteristics and intensive care unit utilization. Crit Care Med. 1993;21:279-291.
42. Corwin HL, Gettinger A, Pearl RG, et al. EPO Critical Care Trials Group. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA. 2002;288:2827-2835.
43. van Iperen CE, Gaillard CA, Kraaijenhagen RJ, Braam BG, Marx JJ, van de Wiel A. Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med. 2000;28:2773-2778.
44. Zimmerman JE, Seneff MG, Sun X, Wagner DP, Knaus WA. Evaluating laboratory usage in the intensive care unit: patient and institutional characteristics that influence frequency of blood sampling. Crit Care Med. 1997;25:737-748.
45. Smoller BR, Kruskall MS. Phlebotomy for diagnostic laboratory tests in adults: pattern of use and effect on transfusion requirements. N Engl J Med. 1986;314:1233-1235.
46. Olivares M, Walter T, Osorio M, Chadud P, Schlesinger L. Anemia of a mild viral infection: the measles vaccine as a model. Pediatrics. 1989;84:851-855.
47. Krantz SB. Pathogenesis and treatment of the anemia of chronic disease. Am J Med Sci. 1994;307:353-359.
48. Means RT Jr, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood. 1992;80:1639-1647.
49. Jurado RL. Iron, infections, and anemia of inflammation. Clin Infect Dis. 1997;25:888-895.
50. Krafte-Jacobs B, Levetown ML, Bray GL, Ruttimann UE, Pollack MM. Erythropoietin response to critical illness. Crit Care Med. 1994;22:821-826.
51. Rogiers P, Zhang H, Leeman M, et al. Erythropoietin response is blunted in critically ill patients. Intensive Care Med. 1997;23:159-162.
52. Krafte-Jacobs B. Anemia of critical illness and erythropoietin deficiency [editorial]. Intensive Care Med. 1997;23:137-138.
53. Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood. 1992;79:1987-1994.
54. Ebert BL, Bunn HF. Regulation of the erythropoietin gene. Blood. 1999;94:1864-1877.
55. Jelkmann W, Pagel H, Wolff M, Fandrey J. Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys. Life Sci. 1992;50:301-308.
56. Batge B, Filejski W, Kurowski V, Kluter H, Djonlagic H. Clostridial sepsis with massive intravascular hemolysis: rapid diagnosis and successful treatment. Intensive Care Med. 1992;18:488-490.
57. Rodriguez RM, Corwin HL, Gettinger A, Corwin MJ, Gubler D, Pearl RG. Nutritional deficiencies and blunted erythropoietin response as causes of the anemia of critical illness. J Crit Care. 2001;16:36-41.
58. Campillo B, Zittoun J, de Gialluly E. Prophylaxis of folate deficiency in acutely ill patients: results of a randomized clinical trial. Intensive Care Med. 1988;14:640-645.
59. Fishbane S. Review of issues relating to iron and infection. Am J Kidney Dis. 1999;34(4, suppl 2):S47-S52.
60. Balla G, Vercellotti GM, Muller-Eberhard U, Eaton J, Jacob HS. Exposure of endothelial cells to free heme potentiates damage mediated by granulocytes and toxic oxygen species. Lab Invest. 1991;64:648-655.
61. Balla J, Jacob HS, Balla G, Nath K, Eaton JW, Vercellotti GM. Endothelial-cell heme uptake from heme proteins: induction of sensitization and desensitization to oxidant damage. Proc Natl Acad Sci U S A. 1993;90:9285-9289.
62. Yalavatti GS, DeBacker D, Vincent JL. Assessment of cardiac index in anemic patients. Chest. 2000;118:782-787.
63. Ho CH. The hemostatic effect of packed red cell transfusion in patients with anemia. Transfusion. 1998;38:1011-1014.
64. Anand A, Feffer SE. Hematocrit and bleeding time: an update. South Med J. 1994;87:299-301.
65. Weigert AL, Schafer AI. Uremic bleeding: pathogenesis and therapy. Am J Med Sci. 1998;316:94-104.
66. Bordin JO, Heddle NM, Blajchman MA. Biologic effects of leukocytes present in transfused cellular blood products. Blood. 1994;84:1703-1721.
67. van de Watering LM, Hermans J, Houbiers JG, et al. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial. Circulation. 1998;97:562-568.
68. Blajchman MA, Hebert PC. Red blood cell transfusion strategies. Transfus Clin Biol. 2001;8:207-210.
69. Blumberg N, Heal JM. Immunomodulation by blood transfusion: an evolving scientific and clinical challenge. Am J Med. 1996;101:299-308.
70. Taylor RW, Manganaro L, O'Brien J, Trottier SJ, Parkar N, Veremakis C. Impact of arogenic packed red blood cell transfusion on nosocomial infection rates in the critically ill patient. Crit Care Med. 2002;30:2249-2254.
71. Hebert PC, Wells G, Blajchman MA, et al. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care [published correction appears in N Engl J Med. 1999;340:1056]. N Engl J Med. 1999;340:409-417.
72. Corwin HL, Gettinger A, Rodriguez RM, et al. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit Care Med. 1999;27:2346-2350.
73. Gabriel A, Kozek S, Chiari A, et al. High-dose recombinant human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfunction syndrome. J Trauma. 1998;44:361-367.
74. Hess JR. Blood substitutes. Semin Hematol. 1996;33:369-378.
75. Gawaz M, Dickfeld T, Bogner C, Fateh-Moghadam S, Neumann FJ. Platelet function in septic multiple organ dysfunction syndrome. Intensive Care Med. 1997;23:379-385.
76. Salat A, Bodingbauer G, Boehm D, et al. Changes of platelet surface antigens in patients suffering from abdominal septic shock. Thromb Res. 1999;95:289-294.
77. Ogura H, Kawasaki T, Tanaka H, et al. Activated platelets enhance microparticle formation and platelet-leukocyte interaction in severe trauma and sepsis. J Trauma. 2001;50:801-809.
78. Nieuwland R, Berckmans RJ, McGregor S, et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood. 2000;95:930-935.
79. Griesshammer M, Bangerter M, Sauer T, Wennauer R, Bergmann L, Heimpel H. Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count. J Intern Med. 1999;245:295-300.
80. Buss DH, Cashell AW, O'Connor ML, Richards F II, Case LD. Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases. Am J Med. 1994;96:247-253.
81. Stephan F, Cheffi MA, Kaplan C, et al. Autoantibodies against platelet glycoproteins in critically ill patients with thrombocytopenia. Am J Med. 2000;108:554-560.
82. Baughman RP, Lower EE, Flessa HC, Tollerud DJ. Thrombocytopenia in the intensive care unit. Chest. 1993;104:1243-1247.
83. Stephan F, Hollande J, Richard O, Cheffi A, Maier-Redelsperger M, Flahault A. Thrombocytopenia in a surgical ICU. Chest. 1999;115:1363-1370.
84. Akca S, Haji-Michael P, de Mendonca A, Suter P, Levi M, Vincent JL. Time course of platelet counts in critically ill patients. Crit Care Med. 2002;30:753-756.
85. Yan SB, Helterbrand JD, Hartman DL, Wright TJ, Bernard GR. Low levels of protein C are associated with poor outcome in severe sepsis. Chest. 2001;120:915-922.
86. Brun-Buisson C, Doyon F, Carlet J, et al. French ICU Group for Severe Sepsis. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults: a multicenter prospective study in intensive care units. JAMA. 1995;274:968-974.
87. Mavrommatis AC, Theodoridis T, Orfanidou A, Roussos C, Christopoulou-Kokkinou V, Zakynthinos S. Coagulation system and platelets are fully activated in uncomplicated sepsis. Crit Care Med. 2000;28:451-457.
88. Mori M, Kudo H, Yoshitake S, Ito K, Shinguu C, Noguchi T. Transient EDTA-dependent pseudothrombocytopenia in a patient with sepsis. Intensive Care Med. 2000;26:218-220.
89. Aird WC, Mark EJ. Case records of the Massachusetts General Hospital: weekly clinicopathological exercises: case 15-200: a 53-year-old man with a myocardial infarct and thromboses after coronary-artery bypass grafting. N Engl J Med. 2002;346:1562-1570.
90. Sheu JR, Hung WC, Wu CH, et al. Reduction in lipopolysaccharide-induced thrombocytopenia by triflavin in a rat model of septicemia. Circulation. 1999;99:3056-3062.
91. Ekstrom BF, Kuenzig M, Schwartz SI. Pulmonary platelet trapping in Escherichia coli endotoxin-injected dogs treated with methylprednisolone, ibuprofen and naloxone. Acta Chir Scand. 1986;152:181-185.
92. Thorne LJ, Jonsson BA, Norgren L, Strand SE. Effect of ticlopidine and prostaglandin E on endotoxin-induced pulmonary platelet sequestration in vivo. Circ Shock. 1986;20:61-69.
93. Shibazaki M, Kawabata Y, Yokochi T, Nishida A, Takada H, Endo Y. Complement-dependent accumulation and degradation of platelets in the lung and liver induced by injection of lipopolysaccharides. Infect Immun. 1999;67:5186-5191.
94. Shibazaki M, Nakamura M, Endo Y. Biphasic, organ-specific, and strain-specific accumulation of platelets induced in mice by a lipopolysaccharide from Escherichia coli and its possible involvement in shock. Infect Immun. 1996;64:5290-5294.
95. Katayama T, Ikeda Y, Handa M, et al. Immunoneutralization of glycoprotein Ibalpha attenuates endotoxin-induced interactions of platelets and leukocytes with rat venular endothelium in vivo. Circ Res. 2000;86:1031-1037.
96. Tsujikawa A, Kiryu J, Yamashiro K, et al. Interactions between blood cells and retinal endothelium in endotoxic sepsis. Hypertension. 2000;36:250-258.
97. Salat A, Murabito M, Boehm D, et al. Endotoxin enhances in vitro platelet aggregability in whole blood. Thromb Res. 1999;93:145-148.
98. Stephan F, Thioliere B, Verdy E, Tulliez M. Role of hemophagocytic histiocytosis in the etiology of thrombocytopenia in patients with sepsis syndrome or septic shock. Clin Infect Dis. 1997;25:1159-1164.
99. Francois B, Trimoreau F, Vignon P, Fixe P, Praloran V, Gastinne H. Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor. Am J Med. 1997;103:114-120.
100. Warkentin TE. Heparin-induced thrombocytopenia: a clinicopathologic syndrome. Thromb Haemost. 1999;82:439-447.
101. Counts RB, Haisch C, Simon TL, Maxwell NG, Heimbach DM, Carrico CJ. Hemostasis in massively transfused trauma patients. Ann Surg. 1979;190:91-99.
102. Geerlings SE, Rommes JH, van Toorn DW, Bakker J. Acute folate deficiency in a critically ill patient. Neth J Med. 1997;51:36-38.
103. Vanderschueren S, De Weerdt A, Malbrain M, et al. Thrombocytopenia and prognosis in intensive care. Crit Care Med. 2000;28:1871-1876.
104. Martinez MA, Pena JM, Fernandez A, et al. Time course and prognostic significance of hemostatic changes in sepsis: relation to tumor necrosis factor-alpha. Crit Care Med. 1999;27:1303-1308.
105. 9/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood. 1998;91:3601-3606.
106. Bernard GR, Vincent J-L,Laterre P-F, et al. Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699-709.
107. White B, Perry D. Acquired antithrombin deficiency in sepsis. Br J Haematol. 2001;112:26-31.
108. Warren BL, Eid A, Singer P, et al. KyberSept Trial Study Group. Caring for the critically ill patient: high-dose antithrombin III in severe sepsis: a randomized controlled trial [published correction appears in JAMA. 2002;287:192]. JAMA. 2001;286:1869-1878.
109. Eisele B, Lamy M, Thijs LG, et al. Antithrombin III in patients with severe sepsis: a randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med. 1998;24:663-672.
110. Fisher CJ Jr,Agosti JM, Opal SM, et al. Soluble TNF Receptor Sepsis Study Group. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med. 1996;334:1697-1702.
111. Abraham E, Anzueto A, Gutierrez G, et al. NORASEPT II Study Group. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet. 1998;351:929-933.
112. Dhainaut JF, Tenaillon A, Hemmer M, et al. BN 52021 Sepsis Investigator Group. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med. 1998;26:1963-1971.
113. Cohen J, Carlet J, International Sepsis Trial Study Group. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. Crit Care Med. 1996;24:1431-1440.
114. Opal SM, Fisher CJ Jr, Dhainaut JF, et al. Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med. 1997;25:1115-1124.
115. van Gorp EC, Suharti C, ten Cate H, et al. Review: infectious diseases and coagulation disorders. J Infect Dis. 1999;180:176-186.
116. Aird WC. Vascular bed-specific hemostasis: role of endothelium in sepsis pathogenesis. Crit Care Med. 2001;29(7, suppl):S28-S34.
117. Pemerstorfer T, Stohlawetz P, Hollenstein U, et al. Endotoxinnduced activation of the coagulation cascade in humans: effect of acetylsalicylic acid and acetaminophen. Arterioscler Thromb Vasc Biol. 1999;19:2517-2523.
118. Suffredini AF,Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med. 1989;320:1165-1172.
119. Philippe J, Offner F, Declerck PJ, et al. Fibrinolysis and coagulation in patients with infectious disease and sepsis. Thromb Haemost. 1991;65:291-295.
120. Faust SN, Levin M, Harrison OB, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med. 2001;345:408-416.
121. Rosenberg RD, Aird WC. Vascular-bed - specific hemostasis and hypercoagulable states. N Engl J Med. 1999;340:1555-1564.
122. Gross PL, Aird WC. The endothelium and thrombosis. Semin Thromb Hemost. 2000;26:463-478.
123. Chakraverty R, Davidson S, Peggs K, Stross P, Garrard C, Littlewood TJ. The incidence and cause of coagulopathies in an intensive care population. Br J Haematol. 1996;93:460-463.
124. Levi M, de Jonge E, van der Poll T, ten Cate H. Novel approaches to the management of disseminated intravascular coagulation. Crit Care Med. 2000;28(9, suppl):S20-S24.
125. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 1999;341:586-592.
126. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M, Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327-1330.
127. Hambleton J, Leung LL, Levi M. Coagulation: consultative hemostasis. Hematology (Am Soc Hematol Educ Program). 2002;335-352.
128. Lorente JA, Garcia-Frade LJ, Landin L, et al. Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest. 1993;103:1536-1542.
129. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23:1638-1652.
130. Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation: compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest. 1992;101:816-823.
131. Coalson JJ, Benjamin B, Archer LT, et al. Prolonged shock in the baboon subjected to infusion of E. coli endotoxin. Circ Shock. 1978;5:423-437.
132. Creasey AA, Chang AC, Feigen L, Wun TC, Taylor FB Jr, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest. 1993;91:2850-2856.
133. Taylor FB Jr, Chang A, Esmon CT, D'Angelo A, Vigano D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest. 1987;79:918-925.
134. Esmon CT. Introduction: are natural anticoagulants candidates for modulating the inflammatory response to endotoxin? Blood. 2000;95:1113-1116.
135. Minnema MC, Chang AC, Jansen PM, et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood. 2000;95:1117-1123.
136. Oelschlager C, Romisch J, Staubitz A, et al. Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells. Blood. 2002;99:4015-4020.
137. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J Biol Chem. 2001;276:11199-11203.
138. Souter PJ, Thomas S, Hubbard AR, Poole S, Romisch J, Gray E. Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood. Crit Care Med. 2001;29;134-139.